EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Delineating clinical and developmental outcomes in STXBP1 -related disorders

Julie Xian, Kim Marie Thalwitzer, Jillian McKee, Katie Rose Sullivan, Elise Brimble, Eryn Fitch, Jonathan Toib, Michael C Kaufman, Danielle deCampo, Kristin Cunningham, Samuel R Pierce, James Goss und 7 weitere

Brain · 01.12.2023 · 146 (12) · 5182-5197

DOI: 10.1093/brain/awad287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 28.11.2023. Verfasst von Julie Xian und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Spasms, Infantile, Epilepsy. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STXBP1-related disorders are among the most common genetic epilepsies and neurodevelopmental disorders. However, the longitudinal epilepsy course and developmental end points, have not yet been described in detail, which is a critical prerequisite for clinical trial readiness. Here, we assessed 1281 cumulative patient-years of seizure and developmental histories in 162 individuals with STXBP1-related disorders and established a natural history framework. STXBP1-related disorders are characterized by a dynamic pattern of seizures in the first year of life and high variability in neurodevelopmental trajectories in early childhood. Epilepsy onset differed across seizure types, with 90% cumulative onset for infantile spasms by 6 months and focal-onset seizures by 27 months of life. Epilepsy histories diverged between variant subgroups in the first 2 years of life, when individuals with protein-truncating variants and deletions in STXBP1 (n = 39) were more likely to have infantile spasms between 5 and 6 months followed by seizure remission, while individuals with missense variants (n = 30) had an increased risk for focal seizures and ongoing seizures after the first year. Developmental outcomes were mapped using milestone acquisition data in addition to standardized assessments including the Gross Motor Function Measure-66 Item Set and the Grasping and Visual-Motor Integration subsets of the Peabody Developmental Motor Scales. Quantification of end points revealed high variability during the first 5 years of life, with emerging stratification between clinical subgroups. An earlier epilepsy onset was associated with lower developmental abilities, most prominently when assessing gross motor development and expressive communication. We found that individuals with neonatal seizures or early infantile seizures followed by seizure offset by 12 months of life had more predictable seizure trajectories in early to late childhood compared to individuals with more severe seizure presentations, including individuals with refractory epilepsy throughout the first year. Characterization of anti-seizure medication response revealed age-dependent response over time, with phenobarbital, levetiracetam, topiramate and adrenocorticotropic hormone effective in reducing seizures in the first year of life, while clobazam and the ketogenic diet were effective in long-term seizure management. Virtual clinical trials using seizure frequency as the primary outcome resulted in wide range of trial success probabilities across the age span, with the highest probability in early childhood between 1 year and 3.5 years. In summary, we delineated epilepsy and developmental trajectories in STXBP1-related disorders using standardized measures, providing a foundation to interpret future therapeutic strategies and inform rational trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spasms, InfantileEpilepsyInfant, NewbornChildChild, PreschoolHumansInfantAnticonvulsantsTopiramateSeizuresMunc18 Proteins

Stichwörter der Autor:innen

STXBP1developmental and epileptic encephalopathygeneticsnatural history studyoutcome measures

Substanzen

AnticonvulsantsTopiramateSTXBP1 protein, humanMunc18 Proteins

Autor:innen und Institutionen

  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA 19146, USA.
  • Epilepsy and Neurodevelopmental Disorders Center (ENDD), Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Division of Pediatric Epileptology, Centre for Pediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Ciitizen Natural History Registry, Invitae, San Francisco, CA 94017, USA.

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • NICHD NIH HHS
  • The Hartwell Foundation
  • National Institute for Neurological Disorders and Stroke
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Intellectual and Developmental Disabilities Research Center

Zitieren

APA

Xian, J., Thalwitzer, K. M., McKee, J., Sullivan, K. R., Brimble, E., Fitch, E., Toib, J., Kaufman, M. C., deCampo, D., Cunningham, K., Pierce, S. R., Goss, J., Rigby, C. S., Syrbe, S., Boland, M., Prosser, B., Fitter, N., Ruggiero, S. M., & Helbig, I. (2023). Delineating clinical and developmental outcomes in STXBP1 -related disorders. Brain, 146(12), 5182-5197. https://doi.org/10.1093/brain/awad287

Vancouver

Xian J, Thalwitzer KM, McKee J, Sullivan KR, Brimble E, Fitch E, et al. Delineating clinical and developmental outcomes in STXBP1 -related disorders. Brain. 2023;146(12):5182-5197. doi:10.1093/brain/awad287

BibTeX
@article{Xian2023,
  author = {Xian, Julie and Thalwitzer, Kim Marie and McKee, Jillian and Sullivan, Katie Rose and Brimble, Elise and Fitch, Eryn and Toib, Jonathan and Kaufman, Michael C and deCampo, Danielle and Cunningham, Kristin and Pierce, Samuel R and Goss, James and Rigby, Charlene Son and Syrbe, Steffen and Boland, Michael and Prosser, Benjamin and Fitter, Nasha and Ruggiero, Sarah M and Helbig, Ingo},
  title = {Delineating clinical and developmental outcomes in STXBP1 -related disorders},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {12},
  pages = {5182--5197},
  doi = {10.1093/brain/awad287}
}
Kostenlos starten →